These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
47. Dyslipidemia: management using optimal lipid-lowering therapy. Ito MK Ann Pharmacother; 2012 Oct; 46(10):1368-81. PubMed ID: 23032652 [TBL] [Abstract][Full Text] [Related]
48. The spectrum of statin myopathy. Mohassel P; Mammen AL Curr Opin Rheumatol; 2013 Nov; 25(6):747-52. PubMed ID: 24061077 [TBL] [Abstract][Full Text] [Related]
49. Is statin-induced diabetes clinically relevant? A comprehensive review of the literature. Bell DS; DiNicolantonio JJ; O'Keefe JH Diabetes Obes Metab; 2014 Aug; 16(8):689-94. PubMed ID: 24373206 [TBL] [Abstract][Full Text] [Related]
50. Statin-associated muscle symptoms: position paper from the Luso-Latin American Consortium. Sposito AC; Faria Neto JR; Carvalho LS; Lorenzatti A; Cafferata A; Elikir G; Esteban E; Morales Villegas EC; Bodanese LC; Alonso R; Ruiz AJ; Rocha VZ; Faludi AA; Xavier HT; Coelho OR; Assad MH; Izar MC; Santos RD; Fonseca FA; Mello E Silva A; Silva PM; Bertolami MC; Curr Med Res Opin; 2017 Feb; 33(2):239-251. PubMed ID: 27776432 [TBL] [Abstract][Full Text] [Related]
51. Evidence supporting primary prevention of cardiovascular diseases with statins: Gaps between updated clinical results and actual practice. Bruckert E; Ferrières J Arch Cardiovasc Dis; 2014 Mar; 107(3):188-200. PubMed ID: 24613429 [TBL] [Abstract][Full Text] [Related]
52. Late onset necrotizing autoimmune myopathy 1 year after cessation of statin treatment. Balke M; Brunn A; Claeys KG; Fink GR; Wunderlich G Acta Neurol Belg; 2019 Sep; 119(3):487-489. PubMed ID: 30008064 [No Abstract] [Full Text] [Related]
53. [Immune-mediated necrotizing myopathy associated with antibodies to hydroxy-methyl-glutaryl-coenzyme A reductase]. Hinschberger O; Lohmann C; Lannes B; Martzolff L; Vo BD; Jaeger-Bizet F; Ciobanu E; Kieffer P Rev Med Interne; 2014 Aug; 35(8):546-9. PubMed ID: 23910221 [TBL] [Abstract][Full Text] [Related]
54. Statin therapy in athletes and patients performing regular intense exercise - Position paper from the International Lipid Expert Panel (ILEP). Katsiki N; Mikhailidis DP; Bajraktari G; Miserez AR; Cicero AFG; Bruckert E; Serban MC; Mirrakhimov E; Alnouri F; Reiner Ž; Paragh G; Sahebkar A; Banach M; Pharmacol Res; 2020 May; 155():104719. PubMed ID: 32087236 [TBL] [Abstract][Full Text] [Related]
55. Current treatment of dyslipidaemia: PCSK9 inhibitors and statin intolerance. Koskinas K; Wilhelm M; Windecker S Swiss Med Wkly; 2016; 146():w14333. PubMed ID: 27400448 [TBL] [Abstract][Full Text] [Related]
56. Management of statin-intolerant patient. Arca M; Pigna G; Favoccia C Panminerva Med; 2012 Jun; 54(2):105-18. PubMed ID: 22525565 [TBL] [Abstract][Full Text] [Related]
57. Autoimmune necrotizing myopathy after statin discontinuation. Abid H; Watthanasuntorn K; Bischof E BMJ Case Rep; 2019 May; 12(5):. PubMed ID: 31092486 [TBL] [Abstract][Full Text] [Related]
58. Intermittent nondaily dosing strategies in patients with previous statin-induced myopathy. Keating AJ; Campbell KB; Guyton JR Ann Pharmacother; 2013 Mar; 47(3):398-404. PubMed ID: 23482733 [TBL] [Abstract][Full Text] [Related]
59. Clinical and laboratory phenotype of patients experiencing statin intolerance attributable to myalgia. Harris LJ; Thapa R; Brown M; Pabbathi S; Childress RD; Heimberg M; Braden R; Elam MB J Clin Lipidol; 2011; 5(4):299-307. PubMed ID: 21784376 [TBL] [Abstract][Full Text] [Related]
60. An assessment by the Statin Cognitive Safety Task Force: 2014 update. Rojas-Fernandez CH; Goldstein LB; Levey AI; Taylor BA; Bittner V; The National Lipid Association's Safety Task Force J Clin Lipidol; 2014; 8(3 Suppl):S5-16. PubMed ID: 24793442 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]